HIV

Brii Biosciences announced $155 million last week in Series C financing.

The press release said the Sino-American biotech will use the proceeds to fund clinical studies and research for its therapies for hepatitis B, Covid-19, multi-drug resistant Gram-negative bacterial infection and HIV, as well as its central nervous system disease program.

The Access to Medicine (AtM) Foundation last week published a pediatric analysis of additional results from its 2021 AtM Index, finding just 7% of pharmaceutical companies’ R&D is for children under 12, despite significant gaps in treatment options for children.

The report praised GSK, Johnson & Johnson and Sanofi for being “the most active” in developing pediatric versions of products, and also named examples of drugs that “could each make a big difference” for LMICs: Eli…

Roche announced last week that WHO has awarded prequalification (PQ) status to the HIV-1 and hepatitis C virus tests on its cobas 6800/8800 Systems.

The company’s Global Access Program—launched in 2014—provides special pricing to LMICs for diagnostic tests for HIV, tuberculosis, hepatitis B and C, and HPV.

Mentions:

On the final day of last week’s annual Conference on Retroviruses and Opportunistic Infections (CROI), Spanish biotech Aelix Therapeutics touted positive topline results from the first-in-human Phase 1/2a trial of its investigational HTI T cell therapeutic vaccine in early-treated people living with HIV.

The AELIX-002 trial evaluated people who interrupted their antiretroviral treatment (ART) after vaccine administration. In a subset of participants who had “a favourable genetic…

Mentions:

Gilead and Merck announced on Monday a deal to co-develop and market long-acting HIV treatments combining Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s nucleoside reverse transcriptase translocation inhibitor candidate, islatravir.

According to the press release, Gilead and Merck will share costs at a ratio of 60% and 40%, respectively, and lead commercialization efforts in different geographies depending on the product formulation.

Mentions:

Merck, Gilead and ViiV captured headlines for their HIV portfolios at this week’s annual Conference on Retroviruses and Opportunistic Infections (CROI).

First, Merck announced on Monday that a reformulated version of its islatravir NRTTI subdermal implant for HIV-1 pre-exposure prophylaxis (PrEP) may provide protection for “at least one year,” based on Phase 1 data. A company researcher told NAM Aidsmap that planned Phase 2 trials of the new version will be “very similar” to the Phase…

Mentions:

GSK subsidiary ViiV asked the U.S. FDA last week to expand the label of Cabenuva—its long-acting injectable combination HIV regimen (containing ViiV’s cabotegravir and J&J’s rilpivirine)—to allow dosing once every two months in addition to the monthly regimen the regulator approved earlier this year.

The move follows The Lancet’s publication in December 2020 of data supporting bimonthly shots.

Mentions:

Adjuvant Capital announced last week a $300 million Global Health Technology Fund focused on accelerating the development of medical innovations for “historically overlooked public health challenges.”

The New York-based social impact investor noted in its press release that it has already backed 14 companies, requiring each to make products broadly accessible to people in low- and middle-income countries. Adjuvant’s “young portfolio” includes investments in companies addressing…

The International AIDS Vaccine Initiative (IAVI) and Scripps Research announced promising results last week from a Phase 1 trial of a novel vaccine approach for HIV.

The eOD-GT8 60mer vaccine compound elicited the targeted antibody response in 97% of participants who received the shot, according to the press release. The Gates Foundation-funded project seeks ultimately to develop a multistep vaccine regimen aimed at eliciting many different types of broadly neutralizing antibodies (…

The Journal of Clinical Investigation Tuesday published positive Phase 1 results from a U.S. National Institute of Allergy and Infectious Diseases trial showing that Maryland-based Emergent BioSolutions’ single-dose intranasal, recombinant, replicating adenovirus influenza vaccine (Ad4-H5-VTN) was safe and produced a durable immune response.

Participants who received the investigational vaccine intranasally or via tonsillar swab had significantly higher H5-specific neutralizing…